Psychedelic medicines for mood disorders: current evidence and clinical considerations : Current Opinion in Psychiatry

Secondary Logo

Journal Logo

MOOD AND ANXIETY DISORDERS: Edited by Santosh K. Chaturvedi, Michael Berk and Wolfgang Marx

Psychedelic medicines for mood disorders: current evidence and clinical considerations

Sarris, Jeromea,b,c,d; Pinzon Rubiano, Diegoa; Day, Kimberleya; Galvão-Coelho, Nicole L.b,e,f; Perkins, Daniela,g,h

Author Information
Current Opinion in Psychiatry 35(1):p 22-29, January 2022. | DOI: 10.1097/YCO.0000000000000759


Purpose of review 

Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions.

Recent findings 

Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity. Randomized placebo-controlled trials have found psilocybin with psychological support effective at treating depression, including treatment-resistant depression; with emergent research also signalling N,N-dimethyltryptamine/ayahuasca also as a potential option for the treatment of depression. Lysergic acid diethylamide has been found to have anxiolytic effects, whereas 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder (PTSD), with Phase III clinical trial evidence. Microdosing of psychedelics is a growing phenomenon that has shown benefits in some preclinical data; however, a recent self-directed controlled trial reported no evidence of improved mood.


Current research with medicinal psychedelics, usually as an adjunct to psychotherapy, has shown encouraging results in treating mood disorders. However, there are challenges regarding blinding and sample sizes remain small, and there have been no definitive Phase III studies (aside from MDMA for PTSD). Further work exploring novel formulations, interface with pharmacogenomics and the microbiome, and inflammatory pathways can be advised.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid